Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.49 |
| ▸ | GLP1R | P43220 | 8/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.46 |
| ▸ | TLR2 | O60603 | 2/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.44 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.44 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.44 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.44 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30019660 | 0.96 | NOD1 (0.50) | NOD1GLP1RSIRT2TLR2CTSS | |
| SCHEMBL27248323 | 0.92 | GLP1R (0.50) | NOD1GLP1RSIRT2TLR2CTSS | |
| SCHEMBL27247789 | 0.92 | GLP1R (0.50) | NOD1GLP1RSIRT2TLR2CTSS | |
| SCHEMBL30020812 | 0.90 | GLP1R (0.46) | NOD1GLP1RSIRT2GNAI3GNAO1 | |
| SCHEMBL30020169 | 0.88 | NOD1 (0.49) | NOD1GLP1RSIRT2TLR2CTSS | |
| SCHEMBL30783472 | 0.88 | NOD1 (0.48) | NOD1SIRT2CTSSCTSKGNAI3 | |
| SCHEMBL27261378 | 0.88 | NOD1 (0.48) | NOD1SIRT2CTSSCTSKGNAI3 | |
| SCHEMBL30020885 | 0.87 | GNAI3 (0.57) | NOD1GNAI3GNAO1GNAI1CAPN1 | |
| SCHEMBL27151464 | 0.86 | GLP1R (0.57) | NOD1GLP1RSIRT2TLR2CTSS | |
| SCHEMBL16318188 | 0.85 | GLP1R (0.55) | NOD1GLP1RSIRT2TLR2CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199663-A1 | Cyclopolyphosphazenes, Related Methods of Preparation and Methods of Use | UNITED STATES DEPARTMENT OF ENERGY | 2024-06-20 | — | — | US | disclosed |
| EP-4326741-A1 | CYCLOPOLYPHOSPHAZENES, RELATED METHODS OF PREPARATION AND METHODS OF USE | University of Saskatchewan (CA) | 2024-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199663-A1 | Cyclopolyphosphazenes, Related Methods of Preparation and Methods of Use | PHOSPHO1, TOP2B, TOP2A | NOD1 514/4885GLP1R 4755/4885SIRT2 4503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.